Shanghai Ruotuo Biotechnology discovers new anti-EGFR/HER3 ADCs
AI Briefing
- • Shanghai Ruotuo Biotechnology Co. Ltd. patents new ADCs targeting EGFR and HER3 for cancer treatment.
- • ADCs link antibodies to cytotoxic drugs, aiming to selectively kill cancer cells.
- • The discovery is intended for the treatment of various types of cancer.
Source Summary
Shanghai Ruotuo Biotechnology Co. Ltd. has patented antibody-drug conjugates (ADCs) comprising bispecific antibodies targeting epidermal growth factor receptors (EGFR; ERBB; HER) and receptor tyrosine-protein kinase erbb-3 (ERBB3; HER3) linked to a cytotoxic drug through a linker intended for use in the treatment of cancer.
Advertisement